HELXvsXBIETF Comparison
VS
Franklin Genomic Advancements ETF (HELX) belongs to the BioTech & Genomics segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. HELX's top 3 sector exposures are Healthcare, Non-Energy Materials and Technology. In contrast, XBI's top sector exposures are Healthcare and Finance. HELX is more expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.35% for XBI. HELX is up 12.93% year-to-date (YTD) with +$6M in YTD flows. XBI performs better with 28.16% YTD performance, and +$399M in YTD flows. Run a side-by-side ETF comparison of HELX and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
HELX vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/11/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | HELX XBI | -1.05%-1.19% | +15.09%+17.80% | +12.93%+28.16% | +33.15%+63.89% | +37.37%+99.44% | -26.59%+19.93% |
| Flows | HELX XBI | --$106M | +$4M+$806M | +$6M+$399M | +$8M+$1.18B | +$15M-$537M | +$4M+$1.48B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | HELX XBI | +24.44%+29.24% | +22.84%+27.93% | +21.42%+28.27% | +23.54%+32.91% |
| Max drawdown | HELX XBI | -6.59%-10.46% | -17.89%-10.46% | -29.16%-32.94% | -58.16%-53.28% |
| Max drawdown duration | HELX XBI | 28d40d | 206d40d | 458d331d | 1814d1622d |
Trading data
HELX | XBI | |
Last sale 9/14/2026 at 1:30 PM | $41.56 | $157.61 |
| Previous close 09/11/2026 | $40.99 | $156.20 |
| Consolidated volume 09/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
HELX
is actively managed and doesn’t replicate an indexHELX | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/14/2026 at 1:30 PM
Live
Closed
HELX | XBI | |
|---|---|---|
| Last price | $41.56 | $157.61 |
| 1D performance | +1.40% | +0.90% |
| AuM | $30.73 M | $10.37 B |
| E/R | 0.5% | 0.35% |
Characteristics
HELX | XBI | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Franklin Templeton | State Street Investment Management |
| Benchmark | - | S&P Biotechnology Select Industry Index |
| N° of holdings | 66 | 149 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | February 25, 2020 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
HELX
USA
86.99%
Other
13.01%
XBI
USA
95.3%
Other
4.7%
Sectors
HELX
Healthcare
96.35%
Other
3.65%
XBI
Healthcare
99.41%
Other
0.59%
Advertisement
Diversification
HELX
Total weight of top 15 holdings out of 15
60.19%
XBI
Total weight of top 15 holdings out of 15
20.29%
Top 15 holdings
Data as of July 31, 2026
HELX
Guardant Health, Inc.
9.10%
Natera, Inc.
7.31%
Krystal Biotech, Inc.
6.17%
Ligand Pharmaceuticals, Inc.
4.48%
Adaptive Biotechnologies Corp.
4.33%
BridgeBio Pharma, Inc.
4.08%
United Therapeutics Corp.
3.52%
Eli Lilly & Co.
3.04%
Vertex Pharmaceuticals, Inc.
2.73%
SAMSUNG BIOLOGICS Co., Ltd.
2.72%
Travere Therapeutics, Inc.
2.67%
Corteva, Inc.
2.65%
AstraZeneca PLC
2.49%
Twist Bioscience Corp.
2.47%
Medpace Holdings, Inc.
2.44%
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
Frequently asked questions about HELX and XBI
How have the HELX and XBI ETFs performed in 2026?
As of September 11, 2026, HELX is up 12.93% year-to-date (YTD), while XBI has returned 28.16%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: HELX or XBI?
Year-to-date, the HELX ETF saw +$6M in flows, compared to +$399M for XBI.
Which ETF is more volatile: HELX or XBI?
Over the past year, HELX had a volatility of 22.84%, while XBI experienced 27.93%.
Which ETF is bigger: HELX or XBI?
As of September 11, 2026, HELX holds $30.73 M in assets under management (AUM), while XBI manages $10.37 B.
What sectors do the HELX and XBI ETFs invest in?
HELX leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the HELX ETF and XBI ETF?
HELX top holdings include Guardant Health, Inc., Natera, Inc. and Krystal Biotech, Inc.. XBI holds in its top three: Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc..
Which ETF is more diversified: HELX or XBI?
HELX holds 66 securities with 60.19% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 20.29%.
Latest news about HELX & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
